The active form of the vitamin can be a key component of a new drug for a hereditary form of the disease, which is now incurable.
Parkinson’s disease is a chronic incurable disease, for which today there are only corrective symptoms therapy. The hereditary form of the disease is associated with mutations in a number of genes, in particular, the gene encoding the LRRK2 enzyme. It was on him that the scientists concentrated to find the key to the potential treatment. And found it in the usual vitamin.
The study was conducted by an international group of scientists, the results are published on the website of the University of the Basque Country.
The team found that the active form of vitamin B12 called AdoCbl is able to inhibit LRRK2.
Scientists tested the effect on brain cell cultures as well as animal models and found that therapy prevents neurotoxicity of LRRK2.
Mutations increase the activity of the kinase enzyme LRRK2, which causes neurotoxicity and other negative effects, the authors explain. For this reason, therapy was aimed specifically at inhibiting this activity, and AdoCbl proved the potential for future research.
“Experimental therapy has proven its neuroprotective properties, which means vitamin B12 can be the basis for the development of new treatments for the hereditary form of Parkinson’s disease,” said scientist.
It is believed that about 15% of patients with Parkinson’s disease have a hereditary form. The overall incidence is constantly growing and, according to experts, the next 25 years will not bring anything good. Experts believe that by 2040 there will be more than 12 million people with this diagnosis. Maybe a few million more.